Monogram Technologies to Be Acquired by Zimmer Biomet, Merger Expected to Conclude in Second Half of 2025
Monogram Technologies Inc. has announced that it will be acquired by Zimmer Biomet. According to the announcement, each common share of Monogram will be cancelled and automatically converted into the right to receive cash and a Contingent Value Right $(CVR)$. The merger is expected to close in the second half of 2025, contingent upon necessary approvals. Monogram shares will continue to be traded on Nasdaq until the merger's completion, after which the company will be delisted and become a wholly-owned subsidiary of Zimmer Biomet.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monogram Technologies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-071242), on July 28, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。